Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566
dc.contributor.author | Nelson, Ryan S. | |
dc.contributor.author | Seligson, Nathan D. | |
dc.contributor.author | Bottiglieri, Sal | |
dc.contributor.author | Carballido, Estrella | |
dc.contributor.author | Del Cueto, Alex | |
dc.contributor.author | Imanirad, Iman | |
dc.contributor.author | Levine, Richard | |
dc.contributor.author | Parker, Alexander S. | |
dc.contributor.author | Swain, Sandra M. | |
dc.contributor.author | Tillman, Emma M. | |
dc.contributor.author | Hicks, J. Kevin | |
dc.contributor.department | Pharmacology and Toxicology, School of Medicine | |
dc.date.accessioned | 2024-12-06T10:57:21Z | |
dc.date.available | 2024-12-06T10:57:21Z | |
dc.date.issued | 2024-10-25 | |
dc.eprint.version | Final published version | |
dc.identifier.citation | Nelson RS, Seligson ND, Bottiglieri S, et al. Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566. Cancers (Basel). 2024;16(21):3595. Published 2024 Oct 25. doi:10.3390/cancers16213595 | |
dc.identifier.uri | https://hdl.handle.net/1805/44790 | |
dc.language.iso | en_US | |
dc.publisher | MDPI | |
dc.relation.isversionof | 10.3390/cancers16213595 | |
dc.relation.journal | Cancers | |
dc.rights | Attribution 4.0 International | en |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.source | PMC | |
dc.subject | UGT1A1 | |
dc.subject | Pharmacogenetics | |
dc.subject | Irinotecan | |
dc.subject | Pazopanib | |
dc.subject | Nilotinib | |
dc.subject | Belinostat | |
dc.subject | Cancer | |
dc.subject | Genotype | |
dc.subject | Precision medicine | |
dc.subject | Gilbert’s syndrome | |
dc.title | Correction: Nelson et al. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers 2021, 13, 1566 | |
dc.type | Article |